[{"id":"4baf504a-3428-46d7-aa11-1c6d5b48f340","acronym":"ACTION-1","url":"https://clinicaltrials.gov/study/NCT05477576","created_at":"2022-07-28T14:55:31.876Z","updated_at":"2025-02-25T17:37:59.568Z","phase":"Phase 3","brief_title":"Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","source_id_and_acronym":"NCT05477576 - ACTION-1","lead_sponsor":"RayzeBio, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • lanreotide prolonged-release subcutaneous • octreotide acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-01-29"},{"id":"076eece4-6905-454a-8a07-8b842556ea06","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595460","created_at":"2022-10-27T15:58:19.568Z","updated_at":"2024-07-02T16:35:01.901Z","phase":"Phase 1","brief_title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","source_id_and_acronym":"NCT05595460","lead_sponsor":"RayzeBio, Inc.","biomarkers":" PD-L1 • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["PD-L1 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-22"}]